Skip to main content
. 2017 Nov 1;34(11):2518–2533. doi: 10.1007/s12325-017-0626-4

Fig. 1.

Fig. 1

Study design. ICF informed consent form, TIO/OLO tiotropium/olodaterol (5/5 µg), UMEC/VI umeclidinium/vilanterol (62.5/25 µg), V study visit